The effect of nuclear transcriptional factor κВ activation inhibitor – curcumine on the experimental immune liver disease by I. N. Alekseyeva, N. V. Makogon, S. I. Pavlovich, T. M. Bryzgina, L. I. Aleksyuk, T. V. Martynova, V. S. Sukhina

Get full text

Time Course of the Development of Nonalcoholic Fatty Liver Disease in the Otsuka Long-Evans Tokushima Fatty Rat by Yi-Sun Song, Cheng-Hu Fang, Byung-Im So, Jun-Young Park, Yonggu Lee, Jeong Hun Shin, Dae Won Jun, Hyuck Kim, Kyung-Soo Kim

“…Nonalcoholic fatty liver disease (NAFLD) is considered a hepatic manifestation of metabolic syndrome. …”
Get full text

Ameliorative Potential of Tamarindus indica on High Fat Diet Induced Nonalcoholic Fatty Liver Disease in Rats by Suja Rani Sasidharan, Joshua Allan Joseph, Senthilkumar Anandakumar, Vijayabalaji Venkatesan, Chandrasekharan Nair Ariyattu Madhavan, Amit Agarwal

“…Nonalcoholic fatty liver disease (NAFLD), the prevalence of which is rising globally with current upsurge in obesity, is one of the most frequent causes of chronic liver diseases. …”
Get full text

Prevalence and factors associated with non-alcoholic fatty liver disease among women with polycystic ovary syndrome by Maria Elisa Franciscatto, Juliana Bosso Taniguchi, Raquel Wohlenberg, Isadora Luísa Riedi, Karen Oppermann

Subjects: “…Non-alcoholic fatty liver disease…”
Get full text

miRNAs and Hematological Markers in Non-Alcoholic Fatty Liver Disease—A New Diagnostic Path? by Agata Michalak, Małgorzata Guz, Joanna Kozicka, Marek Cybulski, Witold Jeleniewicz, Ilona Telejko, Karolina Szczygieł, Ewa Tywanek, Halina Cichoż-Lach

“…Therefore, we decided to explore relationships between selected types of microRNAs (miRNAs), serological markers of liver fibrosis and hematological parameters in the course of non-alcoholic fatty liver disease (NAFLD). <b>Methods:</b> Two hundred and seven persons were included in the survey: 97 with NAFLD and 110 healthy controls. …”
Get full text

Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study by I. Yu. Pirogova, S. V. Yakovleva, T. V. Neuymina, S. P. Sinitsyn, V. S. Chulkov, T. N. Shamaeva

Subjects: “…nonalcoholic fatty liver disease…”
Get full text

Recipients of Early Liver Transplants for Alcohol-Related Liver Disease May Reside in Areas With Lower Social Vulnerability by James Flanary, Elizabeth A. King, FNU Baimaji, Alexandra T. Strauss, Nicole Welch, Annette Bellar, Courtney B. Sherman, Bilal Hameed, Mandana Khalili, Srinivasan Dasarathy, Andrew M. Cameron, Po-Hung Chen

Get full text

Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Leukocytes and Plasma of Children with Nonalcoholic Fatty Liver Disease by Joanna B. Trojanek, Jacek Michałkiewicz, Renata Grzywa-Czuba, Wojciech Jańczyk, Lidia Gackowska, Izabela Kubiszewska, Anna Helmin-Basa, Aldona Wierzbicka-Rucińska, Mieczysław Szalecki, Piotr Socha

“…Gene expression profiles of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) were evaluated in peripheral blood leukocytes of children with nonalcoholic fatty liver disease (NAFLD). Gene expression patterns were correlated with their plasma protein counterparts, systemic parameters of liver injury, and selected markers of inflammation. …”
Get full text

Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD): Trends, Mortality, and Socioeconomic Disparities in the U.S., 1998–2020 by Paul Wasuwanich, Joshua M. So, Mustafa Sadek, Chaowapong Jarasvaraparn, Songyos Rajborirug, Ruben E. Quiros-Tejeira, Wikrom Karnsakul

Subjects: “…fatty liver disease…”
Get full text

Association of leptin receptor Gln223Arg genetic polymorphism with obesity and non-alcoholic fatty liver disease by A. V. Morozova, N. V. Mal'tseva, Y. A. Gorbatovsky, O. F. Lykova, S. V. Arkhipova

Subjects: Get full text

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone by Takamasa Ohki, Akihiro Isogawa, Masahiko Iwamoto, Mitsuru Ohsugi, Haruhiko Yoshida, Nobuo Toda, Kazumi Tagawa, Masao Omata, Kazuhiko Koike

“…Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. Aims. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and pioglitazone. …”
Get full text

Association of Serum Adiponectin, Leptin, and Resistin Concentrations with the Severity of Liver Dysfunction and the Disease Complications in Alcoholic Liver Disease by Beata Kasztelan-Szczerbinska, Agata Surdacka, Maria Slomka, Jacek Rolinski, Krzysztof Celinski, Agata Smolen, Mariusz Szczerbinski

“…There is growing evidence that white adipose tissue is an important contributor in the pathogenesis of alcoholic liver disease (ALD). We investigated serum concentrations of total adiponectin (Acrp30), leptin, and resistin in patients with chronic alcohol abuse and different grades of liver dysfunction, as well as ALD complications. …”
Get full text

Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin by Hamad Abdulsalam Hamad Alfarisi, Muhammad Bin Ibrahim, Zenab B. Hamad Mohamed, Nuraniza Azahari, Asmah Hanim Bt. Hamdan, Che Anuar Che Mohamad

“…Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder worldwide with no curative therapy. …”
Get full text

Association between sleep duration and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis by Kasra Pirahesh, Ali Zarrinnia, Leila Nikniaz, Zeinab Nikniaz

“…Introduction: Considering that both long and short sleep duration may have an association with nonalcoholic fatty liver disease (NAFLD), in this meta-analysis, we analyzed the dose-response association between sleep duration and NAFLD along with meta-analyses of the differences in mean sleep duration between NAFLD patients and healthy controls, and linear meta-analysis of the association between sleep duration and NAFLD. …”
Get full text

Case Report: Cholestatic liver disease in the course of erythropoietic protoporphyria associated with renal hypodysplasia and atrial septal defect by Patryk Lipiński, Agnieszka Lipniacka, Maja Klaudel-Dreszler, Lidia Ziółkowska, Grażyna Kostrzewa, Edyta Odnoczko, Robert Wasilewski, Rafał Płoski, Anna Tylki-Szymańska

“…Progressive cholestatic liver disease (with subsequent congestive heart failure) was observed in the course of EPP. …”
Get full text

Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs by Ye. N. German, M. V. Mayevskaya, O. I. Andreytseva, V. T. Ivashkin, A. V. Chzhao, A. G. Serova, G. V. Mikhaylovskaya, I. Yu. Pirogova

“…According to actual data it was proved, that antibodies to cor-antigen of hepatitis B virus at patients with persistent hepatitis С virus infection do not alter biochemical activity and severity of liver disease. With application of prognostic models tendency to higher risk of end-stages of liver disease development at patients with persistent hepatitis B virus infection and anti-HBcor IgG in blood serum was revealed. …”
Get full text

Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma Patients by Justin Y. Tang, Nitin Ohri, Rafi Kabarriti, Santiago Aparo, Jennifer Chuy, Sanjay Goel, Jonathan M. Schwartz, Milan Kinkhabwala, Andreas Kaubisch, Chandan Guha

“…The significance of short-term changes in model for end-stage liver disease and Sodium (MELD-Na) following hepatocellular carcinoma (HCC) diagnosis is unknown. …”
Get full text

Effect of weight loss on the course of non-alcoholic fatty liver disease: results of 6-month follow-up by L. V. Chesnokova, I. M. Petrov, I. A. Troshina, M. V. Goncharova, I. V. Medvedeva

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Association between non-alcoholic fatty liver disease and progression of abdominal aortic aneurysm: a multicenter study by Ximing Wang, Jingxiang Sun, Na Chang, Menghan Liu, Shuai Zhang

Subjects: “…Non-alcoholic fatty liver disease…”
Get full text

Dietary Interventions and Physical Activity as Crucial Factors in the Prevention and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease by Paweł Rajewski, Jakub Cieściński, Piotr Rajewski, Szymon Suwała, Alicja Rajewska, Maciej Potasz

“…Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and affects nearly 30% of the adult population and 10% of the pediatric population. …”
Get full text